Recently on RedChip's show, Founder and CEO JW Roth explains how VENU offsets amphitheater's cost by pre-selling its luxury fire pit suites, condo-style ownership units inside the venue Combined with municipal partnerships and PACE financing or sale-leasebacks for the rest, VENU builds its venues with little to no equity dilution. Watch the full interview to hear how JW is scaling this model across 40 municipality partnerships nationwide. 👉 Watch the whole interview: redchip.news/4y1qlkJ VENU Holding Corporation is a client of RedChip. Not investment advice. Do your own due diligence. $TKO $MSGE $LYV $SPHR

Join our live investor Q&A with ANIXA - Live Now! xitter.cf/i/broadcasts/1XxygwdmB…

⏳ Starting in 30 Minutes: Anixa Biosciences (Nasdaq: ANIX) Investor Webinar Last chance to join live. In 30 minutes, Anixa Biosciences' Chairman and CEO Amit Kumar will present the Company's breast cancer vaccine program and its path to Phase 2, along with the latest data from its ovarian cancer CAR-T trial. Don't miss your chance to ask questions directly. Register now — starting in 30 minutes. 🔗 Register here: redchip.news/3UPfvA1 Anixa Biosciences is a client of RedChip. Not investment advice. Do your own due diligence. $PFE $AMGN $JNJ $BMRN $CGON $NBTX

RedChip conducted an interview with Co-CEO Bob Brilon of Bimergen Energy (NYSE American: BESS). Brilon discussed the company's battery storage development pipeline and its project-level financing approach, including the use of project-level debt structures and investment tax credit monetization. Management also discussed development fee revenue expectations for 2026 and the company's path toward profitability. Watch Now: redchip.news/4w04usN Bimergen Energy is a client of RedChip. Not investment advice. Do your own due diligence. $NEE $FLNC $BE $ENPH $TSLA $GNRC

VENU Venu Holding ($VENU): Goldman Sachs Expects Steady Live Music Growth Through 2035 Live music ranks among the strongest growth areas in media, according to Goldman Sachs’ latest “Music In The Air” report, which forecasts global music revenue rising from $112.5 billion in 2025 to $198.1 billion by 2035. Goldman projects live music revenue will grow at a mid-single-digit pace every year over that period. Its reasons include higher fan spending, more concerts around the world, the ability of premium experiences to command higher prices, and live shows becoming more central to how artists earn a living. The firm also says consumers continue to put experiences ahead of goods, which supports long-term demand. For Venu, which builds and runs upscale amphitheaters and live music venues focused on premium experiences, these trends point to growing demand for exactly what it offers. Learn more: redchip.com/stocks/venu

RedChip sat down with CEO Frank Basa to discuss Nord's two-track strategy in Canada's Cobalt-Gowganda silver camp: near-term production potential from legacy tailings, plus ongoing exploration at Castle East. Management noted Nord has been invited to submit under Ontario's Recovery Permit framework for its Gowganda tailings, and discussed a multi-year reprocessing timeline. At Castle East, management discussed results from an ongoing drill program identifying multiple vein structures, several of which are under active testing. Watch the full interview: redchip.news/44MxwR4 Nord Precious Metals is a client of RedChip. Not investment advice. Do your own due diligence. $MP $PPTA $TECK $KGC $USGO $HL $NST $CTGO $XAU $XAUUSD

Gorilla Technology Group (Nasdaq: GRRR) has built a contracted AI infrastructure backlog exceeding $5 billion across Indonesia, India, and Thailand, backed by partnerships with NVIDIA, HPE, Intel, Supermicro, Red Hat, and AECOM. Q1 2026 revenue grew 55% year-over-year to $28.2 million, and management raised full-year 2026 guidance to $160–$200 million as GPU deployments in India and Indonesia begin converting backlog into recurring revenue. Read the full report: redchip.news/4gpCQQU Gorilla Technology Group is a client of RedChip. Not investment advice. Do your own due diligence. $GRRR $DGII $CSCO $MSFT $HON $AVGO $ORCL $HPE $FTNT $FYBR $CRWD $DDOG

Recently on RedChip's interview series! Hawkeye Digital (OTC: HWKE) is making a different bet on crypto — not tokens, but equity in the real businesses generating cash flow inside the ecosystem. President David Wachsman explains why he thinks that's the smarter way to get exposure to digital assets right now, and how a decade of relationships across the industry gives Hawkeye a deal-flow edge most investors can't access on their own. Watch the full interview: redchip.news/45Y2W7R Hawkeye Digital is a client of RedChip. Not investment advice. Do your own due diligence. $MSTR $MARA $TSLA $COIN $EXOD $JNJ $ABBV $MRK $SMLR

Craig Shesky, CFO of The Metals Company (Nasdaq: TMC) says the ISA's legal and technical commission has recommended extending TMC's NORI exploration contract, while TMC separately holds priority rights through NOAA's US permitting process. TMC ended Q1 with $160M+ in liquidity, including an untapped credit facility, funding vessel readiness with partner Allseas ahead of Q4 2027 commissioning. A Brownsville, Texas processing facility is in feasibility study, contingent on non-dilutive government funding, positioned on the Gulf's ship channel with deepwater port access. 👉 Full webinar recap at youtube.com/watch?v=6zXH_BL6… The Metals Company is a client of RedChip. Not investment advice. Do your own due diligence. $MOS $NTR $VALE $DAN $CXM

RedChip spoke with Brett Young, CFO of Clinch Resources (TSX: CLCH), about the company's transition from development to production. Young discussed the company's metallurgical coal resource base, permitting status, and estimated life-of-mine cash costs. Management also discussed current metallurgical coal market pricing and the company's production ramp timeline. Watch the full interview here: redchip.news/3Sn2Se4 Clinch Resources is a client of RedChip. Not investment advice. Do your own due diligence. $CEIX $NRP $SXC $BHP $TECK $CLF $NUE $STLD $MT $RS $VALE $FCX $ARLP

FibroBiologics (NASDAQ: $FBLG) Clinical Results in Diabetic Foot Ulcers on the Horizon Houston-based FibroBiologics (Nasdaq: FBLG) is approaching a key milestone, with clinical results expected soon on how its fibroblast-based therapy performs in skin-related conditions such as diabetic foot ulcers. The upcoming data could be an important catalyst as the company advances its pipeline of therapies for chronic diseases. Learn more: redchip.news/4hXpyfA #FBLG #FibroBiologics #DiabeticFootUlcers #WoundHealing #CellTherapy #Biotech #NasdaqStocks #SmallCapStocks

During RedChip's overview with Virax Biolabs (Nasdaq: VRAX), CEO James Foster discussed the diagnostic gap behind Long COVID and chronic fatigue. Foster outlines ViraxImmune, the company's in-development test for post-acute infection syndromes — a category he says carries a major burden in the U.S., and where patients are currently diagnosed mostly through symptoms and exclusion. Watch the overview: redchip.news/4fNqVLp Virax Biolabs is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN $JNJ

In RedChip's exclusive interview with Alliance Entertainment (Nasdaq: AENT),Ken Glaser, SVP of Sales, discussed independent retail's role in the company's broader distribution strategy, noting that these stores often surface consumer demand signals early. Management also discussed year-over-year growth in physical movie and collectibles revenue in Q2 FY26, and pointed to new store openings and younger consumers entering the channel as factors shaping the category. Glaser points to new store openings, younger consumers entering the channel, and artists like Taylor Swift and Olivia Rodrigo leaning into exclusive variants and limited releases as structural — not cyclical — demand drivers. 🔗 Watch the full interview: lnkd.in/eUPcHz2P Alliance Entertainment is a client of RedChip. Not investment advice. Do your own due diligence. $SONY $DIS $PARA $WBD $NTDOY

🧬 Biovie Inc. (Nasdaq: BIVI) CEO Cuong Do walks through the topline results of BioVie's Phase 2 ADDRESS LC trial for bezisterim in Long COVID, and the headline finding is specificity: the drug appears to help patients on whatever symptom they actually have. Do notes 21 of the 22 clinical endpoints assessed favored bezisterim treatment, which he says makes the result unlikely to be due to chance. Do frames this alongside BioVie's recent positive Phase 2 Parkinson's data as validating a broader thesis: that bezisterim is having a real biological effect on CNS function by targeting inflammation and insulin resistance, a mechanism the company believes underlies multiple neurodegenerative and inflammatory conditions. On market size, Do says the trial results reshape BioVie's own estimate of the addressable Long COVID population — up from roughly 4 million severely disabled Americans to potentially 80% of the ~20 million adults living with Long COVID symptoms, a shift he says makes the commercial opportunity substantially larger than originally modeled. 🔗 Watch the full interview: redchip.news/4yFvmzB Biovie Inc. is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN

🧬 Register Now: Anixa Biosciences (Nasdaq: ANIX) Investor Webinar — Today, October 20 at 4:15 PM ET Anixa Biosciences will host a live investor webinar centered on its breast cancer vaccine program — a preventive, off-the-shelf approach built on Phase 1 data that met every primary endpoint. Management will also touch on the Company's ovarian cancer CAR-T program, which continues to show a favorable safety profile at escalating doses. This is a chance to hear directly from leadership as both programs approach key inflection points. Reserve your spot to hear directly from Anixa's Chairman and CEO Amit Kumar. 🔗 Register here: redchip.news/3UPfvA1 Anixa Biosciences is a client of RedChip. Not investment advice. Do your own due diligence. $PFE $AMGN $JNJ $BMRN $CGON $NBTX

BioVie ($BIVI): Phase 2 Parkinson’s Data Show Bezisterim Improved Motor and Non-Motor Symptoms BioVie presented Phase 2 SUNRISE-PD results at the 2026 American Neurological Association Annual Meeting. In the 57-patient trial, patients with higher baseline inflammation showed statistically significant improvements in both motor and non-motor symptoms versus placebo. Across all patients, those on bezisterim were 6.25 times more likely than placebo patients to achieve clinically meaningful improvement (25% vs. 4%). Bezisterim was well tolerated, with no severe or serious adverse events reported, and BioVie said the findings support the design of a potential Phase 3 trial. Full press release: redchip.news/3VVduTq

🧠 Lantern Pharma (NASDAQ: LTRN): http://http://withZeta.ai Positions AI at the Center of Cancer Drug Discovery 90% of new drug discoveries fail in the clinic — costing billions of dollars and decades of lost time. At Nasdaq MarketSite in New York City, Lantern Pharma unveiled withZeta.ai — the company's multi-agentic AI co-scientist platform designed for oncology research and precision drug development. The announcement is notable for investors because withZeta.ai is built to reason across clinical trials, scientific literature, molecular databases, and biomarker data simultaneously — spanning 438 cancer types and compressing years of research into hours. 🔬 Key platform differentiators highlighted: • Multi-agentic AI architecture designed to think alongside researchers • Cross-analysis of oncology datasets, trials, and scientific literature • Proprietary AI infrastructure developed over more than a decade • Focus on cancers with limited treatment options and high unmet need For investors, the key takeaway is Lantern Pharma's positioning at the intersection of artificial intelligence and precision oncology, pairing its clinical-stage oncology pipeline with a differentiated AI-driven discovery platform. LTRN is a client of RedChip. To learn more, click the link! redchip.news/4ec5AKR Lantern Pharma is a client of RedChip. Not investment advice. Do your own due diligence. #LTRN #LanternPharma #AI #BiotechStocks #PrecisionOncology #CancerResearch #DrugDiscovery #ArtificialIntelligence #HealthcareInnovation #Nasdaq #SmallCapStocks

🤖 In this company overview, Exyn Technologies (Nasdaq: EXYN) CEO Ben Williams draws a clear line around what Exyn actually is: not a drone manufacturer, not a robotics provider, but the autonomy software layer — ExynAI, delivered through a payload called the Exyn Nexus. Williams frames the business around four pillars: underground mining, geospatial data collection, OEM software licensing, and government/defense. The common thread is what he calls "continuous ubiquitous digitization," solving physical industries' data problem by digitizing in real time. External users now run more than 1,000 autonomous missions per month across 30+ countries, in conditions Williams says have stress-tested the system in every edge case imaginable. 🔗 Watch the company overview: youtube.com/watch?v=EFDMCKBj… Exyn Technologies is a client of RedChip. Not investment advice. Do your own due diligence. $AVAV $TRMB $TDY $KTOS $OUST $UMAC

OBook Holdings (Nasdaq: OWLS) founder and CEO Darren Wang explains why regulatory licensing is OwlTing's biggest edge over future competitors. The company has spent over four years securing more than 40 U.S. money transmitter licenses, with additional licenses in Europe and across Asia including Japan, Singapore, and Hong Kong. Wang says this global licensing infrastructure is difficult to replicate quickly, positioning OwlTing as a compliant backbone for banks and fintech companies moving money across borders using stablecoins. Watch the full interview: redchip.news/4wpqkFT OBook Holdings is a client of RedChip. Not investment advice. Do your own due diligence. $COIN $PYPL $XYZ $NATL $MARA $RIOT $MSTR $NVDA

RedChip shared a Q2 field update from CEO Christopher Gerteisen on Nova Minerals' (NYSE American: NVA) Estelle project in Alaska. Management reported that the 2026 winter freight haul season was completed ahead of schedule and on budget, with mining and processing equipment now staged on-site. Management discussed the company's antimony production plan, which includes on-site ore sorting ahead of downstream processing at Port MacKenzie. Learn more, and read our disclosures: nvainfo.com Nova Minerals is a client of RedChip. Not investment advice. Do your own due diligence. $MP $PPTA $TECK $KGC $CTGO $XAU $XAUUSD